Wordt geladen...
Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma
Ibrutinib has clear efficacy for activated B-cell-like diffuse large B cell lymphoma (ABC-DLBCL) in previous clinical researches. However, the resistance of Ibrutinib has limited its therapeutic benefit and the potential mechanism remains unclear. This study was aimed to identify potential candidate...
Bewaard in:
| Gepubliceerd in: | Med Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer US
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7904539/ https://ncbi.nlm.nih.gov/pubmed/33629212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-021-01470-5 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|